Daiichi Sankyo Opens Toronto HQ to Accelerate Oncology Care
Toronto, Canada, January 21, 2026 — Daiichi Sankyo, a global healthcare company with more than a century of innovation,...
Alzheimer’s Disease Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody NSCLC Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
Toronto, Canada, January 21, 2026 — Daiichi Sankyo, a global healthcare company with more than a century of innovation,...
Vancouver, British Columbia, December 18, 2025 — Restart Life Sciences Corp., a Canadian-based life sciences company, has successfully closed...
